ストックスクリーナーアプリを入手
0.4031
0.47%
0.0019
前日終値:
$0.4012
開ける：
$0.4
24時間の取引高:
36,127
Relative Volume:
0.19
時価総額：
$6.19M
収益：
$2.73M
当期純損益:
$-19.43M
株価収益率:
-0.1773
EPS:
-2.2739
ネットキャッシュフロー:
$-17.91M
1週間 パフォーマンス:
-16.07%
1か月 パフォーマンス:
-23.80%
6か月 パフォーマンス:
-67.23%
1年 パフォーマンス:
-85.76%
1日の値動き範囲:
$0.391
$0.4144
1週間の範囲:
$0.391
$0.4731
52週間の値動き範囲:
$0.391
$3.23
Traws Pharma Inc Stock (TRAW) Company Profile
Compare TRAW vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
0.4031 | 6.19M | 2.73M | -19.43M | -17.91M | -2.2739 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-06-15 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2025-12-03 | 開始されました | H.C. Wainwright | Buy |
| 2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-05-18 | 開始されました | Guggenheim | Buy |
| 2018-03-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-09 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-27 | 開始されました | Laidlaw | Buy |
| 2015-07-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Traws Pharma Inc (TRAW) 最新ニュース
Traws (TRAW) Shares: Ends Higher by 1.92% at $0.53 in the Current Update; Market Levels: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionATR Stop - vinanet.vn
Traws (TRAW) Shares: Ends Higher by 1.92% at $0.53 in the Current Update; Market Levels: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionHigh Yield Stocks - siam.in
H.C. Wainwright Maintains Traws Pharma(TRAW.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Traws Pharma Ties Up To $50 Million Of Additional Financing To Influenza Regulatory And Clinical Milestones - Pulse 2.0
TRAW Reiterated by HC Wainwright & Co. -- Maintains Price Target at $1.00 - GuruFocus
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 - Investing.com
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com UK
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 - Investing.com
Traws Pharma (NasdaqCM:TRAW) Stock Forecast & Analyst Predictions - Simply Wall Street
Traws Pharma shares rise after Q2 loss comes in better than expected - Yahoo Finance
Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com South Africa
Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com Australia
Traws Pharma beats Q2 loss estimates, shares jump 4% - Investing.com
Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com UK
Traws Pharma beats Q2 loss estimates, shares jump 4% - Investing.com
TRAW Looks 95.6% Undervalued on GF Value™ Amid Price-to-Sales Co - GuruFocus
Ikarian Capital (TRAW) reports 1.56M-share, 9.5% beneficial stake in Traws Pharma - Stock Titan
Traws Pharma Flags Cash Runway Risk Into Q1 2027 Amid FDA Clinical Hold - Minichart
Traws Pharma prepares MHRA resubmission for influenza study - scanx.trade
Traws Pharma Reports Q2 Results, Influenza Program Advances - TipRanks
Traws Pharma Q2 Results: EPS beats estimate, losses widen 45% YoY - scanx.trade
Traws Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Traws Pharma, Inc. Q2 2026: Revenue $0 EPS $(0.16) — 10-Q Summary - TradingView
TRAW: Net loss increased, cash is insufficient for 12 months, and Nasdaq delisting risk remains high - TradingView
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times
Traws Pharma Q2 revenue falls to zero on licensing termination; net loss widens - TradingView
Traws Pharma Reports Q2 2026 Net Loss of $3.0 Million - Quiver Quantitative
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights - GlobeNewswire
Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A - Stock Titan
Sirenia Capital (TRAW) discloses warrant-based stake capped at 9.9% ownership - Stock Titan
Adage Capital reports 4.79% Traws Pharma (TRAW) stake totaling 730,000 shares - Stock Titan
Traws Pharma Q1 2026 Earnings: Net Loss Narrows Sharply, EPS Beats Consensus by 29.78%Analyst Earnings Estimate - dars.gov.et
Traws Pharma Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Traws Pharma Inc (TRAW) Stock News Today - TradingKey
Traws Pharma Inc (NASDAQ: TRAW) Share Price, TRAW Stock News, TRAW Share Price & Updates - Kalkine
Traws Pharma Inc (TRAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
TRAW Q1 2026 Earnings: Loss Narrows 29.8% Versus Estimates as Pre-Revenue Biotech Holds CourseEPS Consistency Score - vinanet.vn
TRAW Q2'26 Earnings: EPS estimate is (0.34) USD - TradingView
TRAW Moves TRX-100 Through Early Human Testing: What Investors Should Watch - tipranks.com
Traws Pharma, Inc. Files Form 8-K: Company Details, NASDAQ Listing, and Compliance Information (July 2026) - Minichart
Traws Pharma Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Traws Pharma, Inc. Revenue Breakdown – NASDAQ:TRAW - TradingView
Traws Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentROIC Trend Report - dars.gov.et
Traws Pharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Traws Pharma Received Notice of Noncompliance - TradingView
Traws Pharma (TRAW) Edges Higher: Micro-Cap Biotech Defends $0.43 SupportHead and Shoulders - vinanet.vn
TRAW Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Traws Pharma Inc (TRAW) Balance Sheet - TradingKey
Traws Pharma Inc (TRAW) 財務データ
収益
当期純利益
現金流量
EPS
1.35%
大文字化:
|
ボリューム (24 時間):